Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.56 |
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | ACHE | P22303 | 8/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610619 | 0.82 | MAOA (0.56) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL10053439 | 0.79 | PYCR1 (0.60) | MAOAMAOBACHETSHR | |
| SCHEMBL10076405 | 0.78 | MAOB (0.68) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL2475627 | 0.75 | MAOA (0.67) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL2475629 | 0.75 | MAOA (0.67) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL10076418 | 0.75 | MAOB (0.71) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL10076415 | 0.75 | MAOB (0.71) | MAOAMAOBACHECYP1A2ADRA2A | |
| Selegiline SCHEMBL4611911 | 0.74 | MAOB (0.90) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL10084811 | 0.74 | MAOA (0.68) | MAOAMAOBACHECYP1A2ADRA2A | |
| SCHEMBL10076400 | 0.73 | MAOB (0.73) | MAOAMAOBACHECYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086860-A2 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GSR, GRIN1, GRIN2A | MAOA 7/4885MAOB 12/4885ACHE 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.